Gilead Sciences (NASDAQ:GILD) reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi sales crushing their expectations. Could Gilead surprise to the upside again? Watch the video below for our take.
David Williamson owns shares of Johnson & Johnson and AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.